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CObjectives: In Singapore, breast cancer is the leading female malig-
nancy and its incidence has increased threefold over the past decades.
For treatment of postmenopausal, hormone receptor positive early
stage breast cancer, tamoxifen or aromatase inhibitors such as anas-
trozole are prescribed either as first-line therapy or sequentially. Cur-
rently, anastrozole is patented with a higher drug cost compared with
tamoxifen. Hence, the aim of this study was to conduct an economic
evaluation of anastrozole versus tamoxifen in early stage breast
cancer. Methods: A Markov model with a lifetime horizon was devel-
oped by using results from the Arimidex, Tamoxifen, Alone or in Com-
bination trial. Direct medical costs were estimated by billing data ob-
tained via financial electronic databases. Utility scores were elicited
from 20 experienced oncology nurses using the visual analogue scale.
Cost per quality-adjusted life-years was calculated by using the soci-
etal perspective. A discount rate of 3% for both charges (expressed in
2010 Singapore dollars) and benefits was used. Results: At an addi- O
e no
culty
al So
oi:10.1016/j.vhri.2012.03.013ional cost of S $17,597, anastrozole treatment resulted in a gain of
.085 life-year survival and 0.154 quality-adjusted life-year. The incre-
ental cost-effectiveness ratio of anastrozole was S $207,402 per life-
ear gained and S $114,061 per quality-adjusted life-year gained com-
ared with tamoxifen. Conclusion: This is the first economic
valuation that used 10-year results from the Arimidex, Tamoxifen,
lone or in Combination trial and utility elicited from the local popu-
ation. If the World Health Organization’s recommendation of 1 to 3
ross domestic product range is an acceptable threshold, anastrozole is
eemed cost-effective compared with tamoxifen in the treatment of
arly stage breast cancer.
eywords: anastrozole, breast cancer, cost-effectiveness analysis, cost-
tility analysis, tamoxifen.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In Singapore, there are more than 6000 newly diagnosed cancer
cases annually [1]. Breast cancer is the leading female malignancy
and constitutes approximately 30% of all female cancers [2]. Al-
though there has been a threefold increase in breast cancer inci-
dence between 1968 and 2002 [3], the mortality of breast cancer
patients has decreased over the years. The 5-year age standard-
ized relative survival was 46.1% from 1973 to 1977 compared with
76.1% from 1998 to 2002 [4], which has translated to an increas-
ingly high cost of illness for breast cancer that amounts to bil-
lions of dollars each year [5–7]. An estimated lifetime per-pa-
tient cost of breast cancer was reported to be between US
$20,000 and US $100,000 [8]. The treatment cost of cancer has
been escalating and will continue to increase, especially with
the discovery of new targeted drugs that would have a signifi-
cant impact on health care resources [9,10]. Because health care
resources are often limited, it would be prudent to choose the
most cost-effective treatment for patients to ensure that re-
sources are efficiently allocated [11].
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ublished by Elsevier Inc.Endocrine therapy is one of the main treatment modalities
for breast cancer and approximately two-third of all breast can-
cer patients are required to receive treatment with endocrine
therapy [12]. Tamoxifen has been advocated as the gold stan-
dard of endocrine treatment over the past few decades and has
been shown to improve both disease-free survival (DFS) and
overall survival [13,14]. One of themajor drawbacks, however, is
its unfavorable side-effect profile such as vaginal bleeding
and/or discharge, endometrial cancer, and thromboembolic
events.
The third-generation aromatase inhibitors (AIs), such as anas-
trozole, are an attractive alternative treatment option among
postmenopausal patients. Currently, there is no consensus re-
garding the duration of therapy with AIs or the optimal sequence
for administration. Nevertheless, numerous clinical practice
guidelines from the American Society of Clinical Oncology, Na-
tional Comprehensive Cancer Network, and St. Gallen Interna-
tional Expert Consensus on the primary treatment of breast can-
cer have advocated the use of AIs as part of adjuvant treatment for
postmenopausal hormone receptor (HR)-positive early stage
breast cancer patients [15–17]. AIs can be prescribed as front-line
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of Science, National University of Singapore, Block S4, 18 Science
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
t
e
o
m
D
p
(
d
(
w
a
w
w
t
h
2
3
47V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 4 6 – 5 3therapy, sequential with tamoxifen, or as extended therapy after 5
years of treatment with tamoxifen.
A large randomized controlled trial, the Arimidex, Tamoxifen,
Alone or in Combination (ATAC) [18–21], has demonstrated both
the efficacy and tolerability of anastrozole as the first-line endo-
crine therapy for postmenopausal HR-positive breast cancer pa-
tients. Anastrozole has been shown to significantly prolong DFS
and reduce the rates of breast cancer recurrences. This trial led to
the approval of anastrozole by the US Food and Drug Administra-
tion for adjuvant treatment of HR-positive early stage breast can-
cer. Anastrozole has a different side-effect profile compared with
tamoxifen and can causemusculoskeletal side effects such asmyal-
gia, arthralgia, and bone loss that can adversely affect the health-
related quality of life (HRQOL) of patients [22]. Currently, anastrozole
is still patented, and its drug acquisition cost is estimated to be ap-
proximately 25 timeshigher than that of tamoxifen (National Cancer
Centre, personal communication, June 2010). The high drug cost
would greatly increase the cost of adjuvant therapy, because most
patients require 5 years of anastrozole treatment.
Althoughmultiple studies have investigated the cost-effective-
ness of various AIs compared with that of tamoxifen [23–29] in
Belgium, Brazil, Canada, Germany, the United Kingdom, and the
United States and reported that anastrozole is cost-effective com-
pared with tamoxifen, none have been conducted in Singapore. It
is essential to perform an economic evaluation of endocrine ther-
apy in breast cancer patients in Singapore because health care
systems and utility scores of patients could differ among coun-
tries, and therefore it may not be appropriate to extrapolate pre-
vious published study results to our local population. Hence, the
objective of this study was to conduct an economic evaluation of
anastrozole, the first AI approved for adjuvant treatment of post-
menopausal womenwith HR-positive early stage breast cancer, in
comparison with tamoxifen by using the ATAC trial as the main
source of effectiveness data. Anastrozole was chosen because the
ATAC trial is the largest adjuvant trial with the longest follow-up
data to date. The results of this study are valuable because they
can assist in health care resource allocation and aid physicians’
decision making during prescribing.
Methods
In theATAC trial, postmenopausal patientswith invasive operable
breast cancer were randomized to anastrozole, tamoxifen, or a
combination of both for up to 5 years on completion of primary
therapy (surgery  radiotherapy  chemotherapy). The combina-
ion arm failed to show any benefit in terms of efficacy or side-
ffects tolerability over tamoxifen alone. The primary end points
f the study were DFS and occurrence of adverse effects. After a
edian of 10 years, anastrozole was demonstrated to improve
FS, time to recurrence, and time to distant recurrencewhen com-
ared with tamoxifen.
A Markov model was constructed by using TreeAge Pro 2009
release 1.0.2) (TreeAge Software, Inc, MA) based on ATAC trial
ata. A hypothetical cohort of 1000 postmenopausal women
mean age of 64 years) with HR-positive early stage breast cancer
ho had completed primary therapy and who were eligible for
djuvant endocrine therapy was used in the model. The patients
ere followed for a lifetime horizon.
A societal perspective was taken but only direct medical costs
ere included in the analysis. Indirect costs were not included in
his study because the mean age of the patients was 64 years and
encemost were not likely to be working. Costs were expressed in
010 Singapore dollars. Costs and benefitswere both discounted at
% per year.Model structure
The structure of the Markov model is shown in Figure 1. A total of
five mutually exclusive health states were defined as no recur-
rence (NR), locoregional recurrence (LR), distant recurrence (DR),
death from breast cancer, and death from other causes [24]. Each
cycle represented 1 year. All patients were assumed to enter the
model under the “no recurrence” health state. At the end of each
cycle, a patient could either remain at the same health state or
move to a different health state on the basis of ATAC trial results.
However, patients at absorbing health states (i.e., death from
breast cancer or other causes) were not allowed to move to other
health states. In addition, patients could only be in one of the five
defined health states at a time and these patients were not al-
lowed to switch between treatment arms.
Model inputs
Data inputs were obtained from the 10-year analysis of the ATAC
trial [18], interviews with oncology nurses, local financial elec-
tronic databases, and published literature.
Recurrence rates for breast cancer were obtained from the
ATAC trial and published literature [18,24]. Using these recurrence
rates, the respective probabilities of general, local, and distant re-
currences were calculated (Table 1). Percentages of patients who
experienced adverse events (AEs) were obtained from the ATAC
trial [20]. The risk of AEs was assumed to be constant over the 5
years of treatment. Mortality rates due to breast cancer after re-
currence were assumed to be similar and constant for both anas-
trozole and tamoxifen [25]. The age-dependent mortality rates for
all causes of the general female populationwere obtained from the
Department of Statistics, Singapore (Table 1) [30].
Resource utilization and costs
The National Cancer Centre (NCCS) is the largest ambulatory can-
cer center in Singapore that treats approximately 70% of all cancer
patients. A retrospective cohort of postmenopausal, HR-positive
early stage breast cancer patients treated at the NCCS with either
anastrozole or tamoxifen adjuvant therapy from January 2001
through December 2009 was reviewed. Patients’ medical records
(both electronic and hard copy) as well as medication dispensing
records from the pharmacy department were accessed. These pa-
tients were then allocated into the three respective different
health states (NR, LR, and DR).
Direct medical costs were estimated from billing data obtained
via financial electronic databases of the NCCS and the Singapore
General Hospital. These medical costs included physicians’ con-
sultation fees, costs of scans, laboratory, and procedures, drug
costs, treatment costs for AEs, and hospitalization (Table 2). In this
study, costs for the NR state for both anastrozole and tamoxifen
included only major costly AEs such as endometrial cancer, spine
fracture, ischemic cardiovascular events, and venous thromobo-
embolism. The cost data were obtained via International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification, codes from the
Singapore General Hospital. All costswere inflated to 2010 costs by
the Singapore consumer price index (health care component)
based on first and second quarter values [31].
Utility measurement
There are various methods to obtain utility values, namely, direct
measurement, published literature, or expert opinion. Although
there is no preferred method, direct measurement can overcome
potential bias from the other two methods due to imprecise esti-
mates and bias from the selection of literature to be used. A tar-
geted literature review was conducted to identify the adverse-ef-
fect profiles of endocrine therapies and their impact on various
health-related quality-of-life aspects. A total of 20 hypothetical
health states and their descriptions were developed and under-
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three breast cancer oncologists and four oncology nurses who had
at least 2 years of experience in oncology. The health state descrip-
tions were reviewed and modified to ensure their accuracy with
regard to symptoms and patients’ feelings, and the level of detri-
ment in each health-related quality-of-life aspect was included.
Health state utilities were elicited through an interview of 20
NCCS oncology nurses with a minimum 2 years of experience in
oncology and were conducted by a trained research assistant.
Health state utility scores were obtained by using the visual ana-
logue scale (VAS). In the VAS, if “dead” was placed at the 0 of the
scale, the utility score for each of the other health states was the
scale value of its placement. However, if being dead was consid-
ered better than the worst health state and placed at some point
between 0 (the worst health state) and 1 (perfect health), scale
recalibrationwas then conducted. The adjusted scorewas equal to
VASadj (raw score score_dead) ⁄ (1 score_dead)
where score_dead is the scale placement of the “dead” state.
Hence, after recalibration, the adjusted utility scores were on a
scale of 0 (dead) and 1 (perfect health). For each health state, the
mean adjusted VAS utility scores and percentages of patients are
Fig. 1 – Simplified strucpresented in Table 3.Data analyses
Cost-effectiveness analyses (CEAs) and cost-utility analyses
(CUAs) were conducted by using the Markov model built. Both the
incremental cost-effectiveness ratio and the incremental cost-
utility ratio (ICUR) were calculated and expressed as cost per life-
year survival and cost per quality-adjusted life-year (QALY)
gained, respectively. To examine the robustness of study results,
multiple one-way sensitivity analyses were performed.
Assumptions made in this study for the construction of the
Markov model are summarized in the Appendix in Supplemental
Materials found at http://dx.doi.org/10.1016/j.vhri.2012.03.013.
Multiple one-way deterministic sensitivity analyses were con-
ducted on key parameters, including the recurrence rates between
anastrozole and tamoxifen, AE rates, treatment costs, utility
scores, and discount rates. For general recurrence rates, 50%
variation in the difference between anastrozole and tamoxifen
was used, whereas15% and20% variation from base values for
LR and DR was used, respectively. Rates of AEs were varied 15%
from base values. For NR costs, 50% variation from the base val-
ues was used, whereas for LR and DR costs, 5th and 95th percen-
tiles from the median were utilized. Utility scores were varied by
using10% variation frombase values. Discount rateswere varied
of the Markov model.turefrom 0% to 8%.
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Cost-effectiveness and cost-utility analyses
Both the CEA and CUA results are presented in Table 4. For the
base-case analysis, themean cost per patient was higher for anas-
trozole (S $36,499) versus tamoxifen (S $19,402). Anastrozole, how-
Table 1 – Probabilities of recurrence rates and age-depende
Year
Recurrence rates
General recurrence [18]
Anastrozole 1–10
11–35
Tamoxifen 1–10
11–35
Local recurrence [24]
Anastrozole/tamoxifen 1–35
Distant recurrence [18]
Anastrozole 1–10
11–35
Tamoxifen 1–35
Age-dependent mortality
Age group (y)
60–64
65–69
70–74
75–79
80–84
85 and above
Table 2 – Estimated costs for medical management and ad
Median/mean costs
(S $ per year)
No recurrence
Drug cost
Anastrozole 9.75 per 1 mg tablet
Tamoxifen 0.4 per 10 mg tablet
Consultation
Anastrozole
Years 1–5 205.08
Years 6–10 51.27
Tamoxifen
Years 1–5 257.05
Years 6–10 51.41
Laboratory
Anastrozole
Years 1–5 30.4
Tamoxifen
Years 1–5 126.21
Scan
Anastrozole/tamoxifen 203.05
Bisphosphonates
Year 1–5 766.97
Calcium 28.8
Locoregional recurrence 4,172.71
Distant recurrence 16,773.59
Adverse events
Endometrial cancer 7,729.57
Ischemic cerebrovascular event 1,779.83
Spine fracture 7,499.23
Venous thromboembolic event 3,322.63
Reference: International Classification of Diseases, Ninth Revision, Clinical
electronic databases from National Cancer Centre Singapore, Singap
* Charges expressed as 2010 Singapore dollars.ever, had a slightly longer overall mean survival compared with
that of tamoxifen (12.96 years vs. 12.87 years, respectively). As for
mean QALYs, it was reported to be 8.26 per patient for anastrozole
and 8.10 per patient for tamoxifen.
Hence, anastrozole resulted in a gain of 0.085 life-year survival
and 0.154 QALYs at an additional charge of S $17,597. The incre-
ortality rates for all causes of the female population.
value Low value High value
0195 0.0174 0.0216
0216 0.0150 0.0193
0237 — —
0216 — —
1758 — —
660 0.460 0.860
600 0.400 0.800
600 0.400 0.800
All-cause mortality [30]
0.0050
0.0097
0.0157
0.0296
0.0473
0.1066
events used in the model*.
SD Low values/5th
percentile
High values/95th
percentile
139.54 65.54 344.62
0 190.81
187.88 69.17 444.93
0 239.29
12.48 300.19
39.76 318.64
83.53 1,381.72
132.35 1,248.25
0 52.58
3,388.69 33,616.02
4,097.23 68,754.26
1,033.57 21,408.83
899.92 2,669.75
3,749.62 11,248.85
871.68 12,606.41
fication, codes from Singapore General Hospital (adverse events) and
ll other charges).nt m
Base
0.
0.
0.
0.
0.
0.
0.
0.verse
Modi
ore (a
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life-year gained and S $114,061 per QALY gained.
Sensitivity analyses
Results ofmultiple one-way sensitivity analyseswere represented
by a tornado diagram (Fig. 2 ). Therewas a 4 times difference in the
ICUR for the general recurrence rates for anastrozole and costs of
NR anastrozole when one-way sensitivity analyses were con-
ducted. Hence, ICURs were sensitive to these two parameters. The
most important inputs for the model were identified to be the
recurrence rates followed by the costs for the NR state (anastro-
zole) and the percentages of patients with spine fracture and en-
dometrial cancer. A summary of multiple one-way analyses con-
ducted is shown in Table 5. In contrast, there were hardly any
differences in the ICUR for percentages of LR or DR patients with
no AE, discount rates, or utilities values.
Table 3 – Percentages of patients and mean adjusted VAS
the model.
Health states Mean adjusted
utility scores
No recurrence
No side effect 0.860
Hip fracture 0.482
Wrist fracture 0.475
Spine fracture 0.372
Vaginal bleeding 0.704
Deep vein thrombosis 0.554
Pulmonary embolism 0.329
Cataract 0.519
Ischemic cerebrovascular events 0.256
Musculoskeletal disorder 0.629
Hot flushes 0.730
Endometrial cancer 0.472
Locoregional recurrence
New contralateral breast cancer 0.468
No side effects 0.491
General side effects 0.473
Distant recurrence
No side effects 0.400
Side effects from chemotherapy 0.365
Side effects from hormonal therapy 0.370
VAS, visual analogue scale.
Table 4 – Cost-effectiveness and cost-utility analyses*.
Cost (C)
(S $)
Incremental
cost
E
Tamoxifen 19,402
Anastrozole 36,999 17,597
Cost (C)
(S $)
Incremental
cost (S $)
E
Tamoxifen 19,402
Anastrozole 36,999 17,597
ICER, incremental cost-effectiveness ratio; LYG, life-years gained; QA
* Charges expressed in 2010 Singapore dollars.Discussion
Our study findings were similar to those of other published CEA
and CUA studies that compared anastrozole to tamoxifen as first-
line therapy [23–29]. Majority of the studies utilized ATAC trial
efficacy data at 5 years and utility data obtained from published
literature. Regardless of the perspectives chosen and countries
where studies were conducted, all of them demonstrated that
anastrozole was more cost-effective than tamoxifen, with ICURs
ranging from approximately S $7118 to S $96,752.
One-way sensitivity analysis would allow a single variable to
vary over a range of possible values based on assumptions made
and to determine the robustness of study results. Based on the
multiple one-way sensitivity analyses conducted, results were con-
sistent with other published studies in which ICURs were largely
dependent on recurrence rateswhereas utilities andAE rates did not
impact study results [24,26,27,29]. As demonstrated by Lux et al. [29],
the singlemost importantmodel inputwas the hazard ratio for time
y scores for various health descriptions/states used in
SD Percentages of patients (%) [20]
Anastrozole Tamoxifen
0.12 6.60 0.60
0.17 1.20 1.00
0.20 2.30 2.00
0.21 1.50 0.90
0.21 5.40 10.20
0.21 1.6 2.40
0.20 1.20 2.10
0.18 5.90 6.90
0.19 2.00 2.80
0.18 35.60 29.40
0.18 35.70 40.90
0.23 0.20 0.80
0.18 1.00
0.23 3.60
0.28 95.40
0.25 3.60
0.26 48.20
0.28 48.20
iveness
(LYG)
Incremental
effectiveness
C/E ICER
.873 1507
.958 0.085 2855 207,402
iveness
QALY)
Incremental
effectiveness
C/E ICER
.101 2395
.255 0.154 4482 114,061
uality-adjusted life-years.utilit
VASffect
(E)
12
12
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8
8
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51V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 4 6 – 5 3to recurrence. Similarly, in this study, the top three crucial model
inputswere all related to recurrence rates suchas general recurrence
rates, rate of DR for tamoxifen, and rate of LR to DR.
This study has a few strengths. First, most studies used the
5-year completed analysis data from the ATAC trial except for one
study [29] that used 100-month analysis data. However, our study
sed the most updated 10-year analysis results from the ATAC
rial. With the availability of 10-year analysis results, previous
Fig. 2 – Tornado diagram for incremental cos
Table 5 – Summary of multiple one-way sensitivity analys
Sensitivity analysis Incremental
costs (S $)
Base case 18,000
Discount rate
0% 18,841.22
4% 17,208.72
8% 15,779.37
Costs for NR anastrozole
50% decrease 20,774.30
50% increase 81,386.27
Costs for NR tamoxifen
50% decrease 19,654.70
50% increase 6,097.58
General recurrence rates for anastrozole
50% decrease in difference 16,389.86
50% increase in difference 17,747.42
LR to DR rate
15% decrease 17,556.67
15% increase 17,639.60
DR rate for anastrozole
20% decrease 17,806.06
20% increase 17,388.61
DR rate for tamoxifen
20% decrease 17,361.23
20% increase 17,833.45
% DR patients, no AE
15% decrease 17,597.34
15% increase 17,597.34
% LR patients, no AE
15% decrease 17,597.34
15% increase 17,597.34
AE, adverse event; DR, distant recurrence; LR, local recurrence; NR, n
* $ expressed in 2010 Singapore dollars.tudies’ assumption of a carryover effect over the next 5 years
fter adjuvant treatment was not necessary. In addition, com-
ared with other studies, our study model was strengthened by
tilizing retrospective data from local patient population to esti-
ate resource consumptions instead of relying on expert opinion
r using published literature as data inputs.
Another unique feature of our study model was its input for
tility values. A majority of studies used utility values obtained
LY comparing anastrozole with tamoxifen.
sults*.
Incremental
QALYs
Incremental cost-utility ratio
(S $ per QALY)
0.154 114,061
0.22 86,242
0.14 123,954
0.1 165,332
0.15 134,653
0.15 527,522
0.15 127,396
0.15 39,523
0.32 51,552
0.08 216,652
0.12 145,824
0.17 106,635
0.24 75,491
0.07 239,210
0.07 258,038
0.24 73,912
0.15 113,800
0.15 115,160
0.16 113,178
0.15 117,893
urrence; QALY, quality-adjusted life-years.t/QAes re
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cited the study by Sorensen et al. [33] that had been published only
in an abstract form. Because utility values differ among various
countries, it would be an added advantage to use utility values
elicited from the local population. In this study, preferences of
health care professionals were utilized. They can be viewed as an
“intermediate” population acting as proxy for patients. To date,
there is no agreementwith regard to the population that should be
approached for the measurement of utility values [34,35]. Using
patients and the general population as the source of utility esti-
mates both have their own set of limitations; for example, “ceiling
effect” and “floor effect” may occur, respectively [36]. Instead,
more importantly, preferences should be chosen on the basis of
the perspective of the study.
To the best of our knowledge, this is the first economic evalu-
ation to address the role of anastrozole over tamoxifen in the
treatment of postmenopausal early stage breast cancer patients in
Asia. Currently, in Singapore, the Pharmacoeconomics and Drug
Utilization Unit, established in 2001, conducts ongoing reviews
and revisions to the standard drug list. The standard drug list
contains essential drugs that have to be available at affordable
prices at public health care institutions. Both CEA and CUA studies
are beneficial in assisting decision making with regard to reim-
bursement issues and the prescribing of medications.
Adjuvant endocrine therapy comprises tamoxifen and AIs. Al-
though AIs have been shown to have better DFS and overall sur-
vival and possess a different side-effect profile compared with
tamoxifen, their drug acquisition costs are much higher. By con-
ducting CEA or CUA studies, long-term effects such as AEs and the
effectiveness of drug therapy can be predicted and this would help
with physicians’ decision making and resource allocation.
To date, there is no fixed acceptable cost-effectiveness thresh-
old that has been defined in Singapore and no consensus among
different countries. An acceptable reimbursement range in the
United States has been reported to be US $50,000 to US $100,000
per QALY gained [37,38]. In the United Kingdom, according to the
National Institute for Health and Clinical Excellence, a conven-
tional threshold is €20,000 to €30,000 per QALY [39]. The World
ealth Organization has proposed to use a country’s per-capita
ross domestic product (GDP) to establish thresholds. If the value
s worked out to be equal or less than 3 times the GDP, then the
rug therapy in question would be considered as cost-effective
40]. Using this as a reference, Singapore’s 2010 per-capita GDPwas
eported at S $59,813 from the Department of Statistics [41]; there-
ore, an acceptable threshold would be S $179,439. In this study,
he ICUR was reported to be S $114,061 per QALY gained. As such,
nastrozole may be considered cost-effective.
There are several limitations in this study. First, cost data were
btained from a retrospective cohort of patients and estimation
ad to be made on long-term cost data (e.g., 10 years) for patients
n anastrozole because data were not available. In addition, costs
or major AEs that often required hospitalization were taken from
nly one institution, which may not be representative of other
ospitals. Another potential limitationwas that utility values used
ere obtained from the VAS method that has generally been con-
idered to be less preferred compared with standard gamble and
ime trade-off methods [42]. In several similar studies, standard
amble was used [26,27,29] whereas the others did not indicate
explicitly. There seems to be evidence that utility obtained via VAS
may not necessarily be inferior compared with that obtained via
standard gamble [43] but further research is needed to ascertain
that. Moreover, because the utility scores were obtained from a
small group of nurses, great variation in the utility scores was
observed and the study results may be sensitive to utility scores
used. With pharmacoeconomic models, assumptions are neces-
sary because it is not feasible to include all possible event occur-
rences and to have all data inputs available. Although multipleone-way sensitivity analyses for key parameters of the models
were conducted, there could be an underestimation of uncertainty
because they are not able to capture potential interaction among
the various parameters. Besides, selection biasmay occur because
of the lack of consensus regarding which variables and range of
values to be adjusted.
Pharmacoeconomic modeling would be useful in an era
whereby there are escalating costs coupledwith limited resources.
Economic analyses have numerous potential applications in pol-
icy decision making [44] such as reimbursement issues, negotia-
tion of drug prices [45], and development of clinical practice guide-
lines. It is also important to present all information available
clearly that would subsequently allow policymaking to be trans-
parent. Future research may include comparison of sequential ta-
moxifen with anastrozole or with other AIs and comparison be-
tween two AI therapies such as letrozole and anastrozole in
adjuvant treatment of breast cancer. Economic evaluation of such
studies would definitely be an added piece of useful information
for drug prescribing because clinical data have not been able to
determine the optimal duration of AI and sequence.
Conclusion
If the World Health Organization’s recommendation of 1 to 3 GDP
range is an acceptable threshold, our study results suggest that
although anastrozole has a higher drug acquisition cost, its use
over tamoxifen in the treatment of postmenopausal early stage
breast cancer can be justified in Singapore based on both effective-
ness and utility data.
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